Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42486225.
- Also identified by DOI 10.1016/j.mayocp.2026.07.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To examine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and alcohol intake in a large cohort of outpatient adults who currently drink. We conducted a retrospective analysis of 11,258 participants seen at the Cooper Clinic (Dallas, Texas) from January 2, 2008, to July 22, 2024, comparing changes in self-reported weekly alcohol intake between adults who were initiated on a GLP-1RA (n =256) versus a control group (n =11,002) that did not receive a GLP-1RA. A linear mixed-effects model was used to estimate changes in alcohol intake, adjusting for time between visits, age, sex, glucose level, and weight. The GLP-1RA treatment group had a greater reduction in weekly alcohol intake than the control group (-1.0 drinks/week; 95% CI -1.6 to -0.4; P =.002), which became non-significant after adjusting for weight change (P =.10). GLP-1RA treatment was associated with a reduction in alcohol intake. This effect was attenuated when controlling for weight loss. The findings suggest a reduction in alcohol use with GLP-1RAs that was related to a reduction in weight.